SCHEDULE: Adage Capital Reduces Soleno Therapeutics Stake to 2.64%

Adage Capital Management, L.P. and its principals have reduced their beneficial ownership in Soleno Therapeutics Inc. to 2.64% of common stock.

Summary

• Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross collectively beneficially own 1,401,576 shares of Soleno Therapeutics Inc. common stock.
• This ownership represents 2.64% of the company's outstanding common stock.
• The percentage is calculated based on 53,145,009 shares of common stock outstanding as of August 1, 2025, as reported in the Company's Quarterly Report on Form 10-Q.
• This filing is an Amendment No. 6 to a previous Schedule 13G, indicating a reduction in their stake to below the 5% reporting threshold.
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the reduction in beneficial ownership by a significant institutional investor to below the 5% reporting threshold, which can be interpreted as a lack of conviction or a strategic divestment.

Positives

• NA

Negatives

• Adage Capital Management, L.P. and its principals have reduced their beneficial ownership in Soleno Therapeutics Inc. to below 5%, suggesting a decrease in their investment.

Risks

• The filing itself does not detail specific risks of Soleno Therapeutics Inc.; it is a disclosure of ownership.

Future Outlook

NA

Industry Context

This filing reflects a change in institutional investor positioning within the biotechnology or pharmaceutical sector, specifically concerning Soleno Therapeutics Inc. The reduction of a significant stake by a prominent investment manager like Adage Capital Management could be interpreted by the market as a shift in investment strategy or a re-evaluation of the company's prospects, though the filing itself provides no rationale.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: May view the reduction in institutional ownership as a negative signal, potentially impacting investor confidence and share price.
• Company Management: Could face questions regarding the reasons for the institutional investor's reduced stake.

Next Steps

• NA

Key Dates

Recommendation

The reduction of a significant institutional stake by Adage Capital Management to below 5% suggests a lack of conviction or a strategic divestment. While the filing provides no explicit rationale, such a move by a sophisticated investor often signals a re-evaluation of the company's prospects or a shift in capital allocation, which could put downward pressure on the stock. Investors might consider reducing their exposure or re-evaluating their own investment thesis in light of this institutional selling.

Keywords

Soleno Therapeutics, Adage Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Equity Stake, SEC Filing